ESTIMATION OF CREATININE CLEARANCE WITHOUT 24-HOUR URINE COLLECTION - A USEFUL GUIDE DURING CISPLATIN THERAPY

被引:15
作者
HAIM, N
OMAN, SD
GALAI, N
BURDE, B
NATHAN, S
CATANE, R
机构
[1] HEBREW UNIV JERUSALEM,HADASSAH HOSP,DEPT ONCOL,JERUSALEM,ISRAEL
[2] HEBREW UNIV JERUSALEM,DEPT STAT,JERUSALEM,ISRAEL
关键词
D O I
10.3109/02841869309093618
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The validity of the Cockroft and Gault formula in monitoring renal function during cisplatin therapy was examined in 110 consecutive cancer patients. A good correlation between estimated creatinine clearance (ECC) and the standard measured creatinine clearance (MCC) was found both before and after the onset of cisplatin. The correlation was better in males (r = 0.78 prior to cisplatin and r = 0.79 after the initiation of cisplatin) than in females (r = 0.69 and r = 0.63 respectively). Obesity ( > 125% of ideal body weight) had no major effect on the correlation between ECC and MCC. The presence of third-space body fluids, on the other hand, had an influence on the relations between ECC and MCC, particularly in females (r = 0.49). It is concluded that estimation of creatinine clearance, without the cumbersome collection of 24-h urine specimens, is accurate enough for the purpose of adjusting cisplatin dose. It should not be used in females with third-space body fluids.
引用
收藏
页码:409 / 412
页数:4
相关论文
共 9 条
[1]  
CHABNER BA, 1985, CANCER PRINCIPLES PR, V2, P287
[2]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[3]  
DAVILA E, 1987, CANCER, V60, P161, DOI 10.1002/1097-0142(19870715)60:2<161::AID-CNCR2820600206>3.0.CO
[4]  
2-V
[5]   ESTIMATING CREATININE CLEARANCE IN MORBIDLY OBESE PATIENTS [J].
DIONNE, RE ;
BAUER, LA ;
GIBSON, GA ;
GRIFFEN, WO ;
BLOUIN, RA .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1981, 38 (06) :841-844
[6]   URINARY CREATININE EXCRETION AND LEAN BODY-MASS [J].
FORBES, GB ;
BRUINING, GJ .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1976, 29 (12) :1359-1366
[7]  
IGNOFFO R, 1988, P AM SOC CLIN ONCOL, V7, P67
[8]  
MCDERMOTT DF, 1987, CANCER TREAT REP, V71, P1067
[9]  
1959, STAT B METROP LIFE I, V40